BV-R2 combination shows survival benefit across high-risk subgroups.
Ami Ali, PharmD, BCOP
Advertisement
Articles by Ami Ali, PharmD, BCOP
The FDA approved acalabrutinib as a frontline option for untreated mantle cell lymphoma.
The approval marks a significant milestone in the treatment of a rare and aggressive subtype of acute leukemia.
Pharmacists will play a significant role in TKI adherence rates among patients.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Recognizing Immunizing Pharmacists in the Community
2
PCV20 Demonstrates Real-World Effectiveness Against Pneumonia in Older Adults
3
FDA Grants Interchangeability Designation to Denosumab Biosimilars Stoboclo and Osenvelt
4
Improving RSV Vaccine Coverage Could Prevent Thousands of Severe Cases in Older Adults
5
